Switchable membrane remodeling and antifungal defense by metamorphic chemokine XCL1

*Acacia F. Dishman[1 †] and Michelle W. Lee[2 †], Jaime de Anda[2], Ernest Y. Lee[2, 3], Jie He[4], Anna R. Huppler[4], Gerard C. L. Wong[2] and Brian F. Volkman[1] **

[1]Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226 USA

[2]Department of Bioengineering, University of California Los Angeles, Los Angeles, CA 90095, USA

[3]UCLA-Caltech Medical Scientist Training Program, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

[4]Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226 USA

[†] These authors contributed equally to this work

*Corresponding Author: Brian F. Volkman, bvolkman@mcw.edu

Supplemental Figure 1.



Fig. S1.SAXS spectra for SUVs alone. To facilitate visualization, spectra have been manually offset in the vertical direction by scaling each trace by a multiplicative factor.

Supplemental Figure 2.



Fig. S2.Protein-only SAXS spectra for all proteins tested in this study. To facilitate visualization, spectra have been manually offset in the vertical direction by scaling each trace by a multiplicative factor.

Supplemental Figure 3.



Fig. S3.SAXS spectra for XCL1 structural variants incubated with model mammalian cell membranes (DOPS/DOPE/DOPC 20/40/40). To facilitate visualization, spectra have been manually offset in the vertical direction by scaling each trace by a multiplicative factor.